Article ; Online: Sorafenib induces cardiotoxicity through RBM20-mediated alternative splicing of sarcomeric and mitochondrial genes.
2023 Volume 198, Page(s) 107017
Abstract: Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line treatment for advanced solid tumors, but it induces many adverse cardiovascular events, including myocardial infarction and heart failure. These cardiac defects can be mediated by ... ...
Abstract | Sorafenib, a multi-targeted tyrosine kinase inhibitor, is a first-line treatment for advanced solid tumors, but it induces many adverse cardiovascular events, including myocardial infarction and heart failure. These cardiac defects can be mediated by alternative splicing of genes critical for heart function. Whether alternative splicing plays a role in sorafenib-induced cardiotoxicity remains unclear. Transcriptome of rat hearts or human cardiomyocytes treated with sorafenib was analyzed and validated to define alternatively spliced genes and their impact on cardiotoxicity. In rats, sorafenib caused severe cardiotoxicity with decreased left ventricular systolic pressure, elongated sarcomere, enlarged mitochondria and decreased ATP. This was associated with alternative splicing of hundreds of genes in the hearts, many of which were targets of a cardiac specific splicing factor, RBM20. Sorafenib inhibited RBM20 expression in both rat hearts and human cardiomyocytes. The splicing of RBM20's targets, SLC25A3 and FHOD3, was altered into fetal isoforms with decreased function. Upregulation of RBM20 during sorafenib treatment reversed the pathogenic splicing of SLC25A3 and FHOD3, and enhanced the phosphate transport into mitochondria by SLC25A3, ATP synthesis and cell survival.We envision this regulation may happen in many drug-induced cardiotoxicity, and represent a potential druggable pathway for mitigating sorafenib-induced cardiotoxicity. |
---|---|
MeSH term(s) | Rats ; Animals ; Humans ; Alternative Splicing ; Sorafenib ; Cardiotoxicity/genetics ; Cardiotoxicity/metabolism ; Sarcomeres/metabolism ; Genes, Mitochondrial ; RNA-Binding Proteins/genetics ; RNA-Binding Proteins/metabolism ; Myocytes, Cardiac/metabolism ; Adenosine Triphosphate/metabolism ; Formins/genetics ; Formins/metabolism |
Chemical Substances | Sorafenib (9ZOQ3TZI87) ; RNA-Binding Proteins ; Adenosine Triphosphate (8L70Q75FXE) ; FHOD3 protein, human ; Formins ; RBM20 protein, rat |
Language | English |
Publishing date | 2023-11-23 |
Publishing country | Netherlands |
Document type | Journal Article |
ZDB-ID | 1003347-6 |
ISSN | 1096-1186 ; 0031-6989 ; 1043-6618 |
ISSN (online) | 1096-1186 |
ISSN | 0031-6989 ; 1043-6618 |
DOI | 10.1016/j.phrs.2023.107017 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 721: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.